GeneTex
United States (US)

Factor VIII antibody [102]

Cat No. GTX40474

Host Mouse
Clonality Monoclonal
Clone Name 102
Isotype IgG1
Application IA
Reactivity Human
APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.
Application Dilution
IA Assay dependent
Not tested in other applications.

Calculated MW

267 kDa kDa. ( Note )

Specificity/Sensitivity

GTX40474 recognizes full-length human Factor VIII. It does not cross-react with von Willebrand factor.
PROPERTIES

Form

Liquid

Buffer

Preservative: 0.01% Sodium Azide. Constituents: PBS, Ascites. pH 7.4

Antigen Species

Human

Immunogen

Full length native protein (purified): human Factor VIII

Conjugation

Unconjugated

Note

For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Cellular Localization

Secreted

Background

Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. It is an extracellular factor. Defects in F8 are the cause of hemophilia A (HEMA). HEMA is a common recessive X linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50% of patients have severe hemophilia A with F8C activity less than 1% of normal; they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10% of patients; F8C activity is 2-5% of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40% of patients, is associated with F8C activity of 5-30% and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8C in their plasma (at least 30% of normal), but the protein is nonfunctional; i.e., the F8C activity is much less than the plasma protein level. CRM reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.
Show More +

Database

Package List Price ($)
$ 289